Details
Stereochemistry | RACEMIC |
Molecular Formula | C25H31NO |
Molecular Weight | 361.5197 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@](O)(CCN1C[C@]3([H])C4=CC=CC=C4CCC5=CC=CC2=C35)C(C)(C)C
InChI
InChIKey=ZZJYIKPMDIWRSN-TZBSWOFLSA-N
InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m1/s1
Molecular Formula | C25H31NO |
Molecular Weight | 361.5197 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/355181
Sources: https://www.ncbi.nlm.nih.gov/pubmed/355181
Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/908278 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. | 1990 Nov |
|
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. | 1991 Apr 18 |
|
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. | 1993 Aug |
|
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. | 1993 Sep 15 |
|
Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. | 1994 Jan |
|
Expression and pharmacological characterization of the human D3 dopamine receptor. | 1994 Jan |
|
Characterization of the human dopamine D3 receptor expressed in transfected cell lines. | 1994 Jan 1 |
|
High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. | 1994 Nov 11 |
|
Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. | 1995 Dec |
|
Lack of discrimination by agonists for D2 and D3 dopamine receptors. | 1995 Jul |
|
Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. | 1996 Dec |
|
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. | 1998 Aug 21 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/913230
Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7003
Curator's Comment: The effects of the two enantiomers of butaclamol and of several neuroleptics on the apomorphine-elicited inhibition of synaptosomal tyrosine hydroxylase activity was investigated. The (+) but not the (-) enantiomer of butaclamol reverses the apomorphine-elicited enzyme inhibition. (+) Butaclamol is more potent than the other tested neuroleptics.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:10:28 GMT 2023
by
admin
on
Fri Dec 15 16:10:28 GMT 2023
|
Record UNII |
A7A2802VNL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Butaclamol
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
100000088474
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
DTXSID5048429
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
3478
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
C81088
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
SUB05995MIG
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
D002069
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
36504-93-5
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
A7A2802VNL
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
73298
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
37461
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL8514
Created by
admin on Fri Dec 15 16:10:28 GMT 2023 , Edited by admin on Fri Dec 15 16:10:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Binding Assay
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|